{"id":"NCT02825251","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid速 in Adults With Type 1 Diabetes","officialTitle":"Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid速 in Adults With Type 1 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-06","primaryCompletion":"2017-06-20","completion":"2017-07-21","firstPosted":"2016-07-07","resultsPosted":"2018-07-24","lastUpdate":"2019-11-21"},"enrollment":472,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"Faster-acting insulin aspart","otherNames":[]},{"type":"DRUG","name":"insulin aspart","otherNames":[]}],"arms":[{"label":"Faster-acting insulin aspart CSII","type":"EXPERIMENTAL"},{"label":"NovoRapid速 CSII","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid速 in Adults with Type 1 Diabetes.","primaryOutcome":{"measure":"Change in Glycosylated Haemoglobin (HbA1c)","timeFrame":"Week 0, week 16","effectByArm":[{"arm":"Faster Aspart","deltaMin":7.49,"sd":0.55},{"arm":"NovoRapid","deltaMin":7.49,"sd":0.53}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":92,"countries":["United States","Belgium","Canada","France","Germany","Netherlands","Russia","Slovenia","United Kingdom"]},"refs":{"pmids":["28918652","30537180","34524005"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":236},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Infusion site reaction","Gastroenteritis"]}}